Diosynth Biotechnology (Research Triangle Park) Announces Agreement With ImmunoGen, Inc. (IMGN) 
10/19/2005 5:13:18 PM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Oct. 6, 2005--Diosynth Biotechnology, Inc. is pleased to announce the execution of an agreement with ImmunoGen, Inc. (Cambridge, MA) for the production of antibody to be used in the manufacture of ImmunoGen's huN901-DM1 anticancer compound.